MPI
United States
MPI
United States

Time filter

Source Type

News Article | May 8, 2017
Site: www.prnewswire.com

Below are the key highlights of the products displayed at Inspur booth (#911): The SR-AI Rack, jointly launched by Inspur and Baidu at Inspur Partner Forum (IPF) 2017 on April 26, is the world's first rack server that adopts a PCI-e Fabric interconnect architecture design. It breaks the traditional server GPU/CPU coupled architecture through connecting the upward CPU computing/scheduling node to the downward GPU Box using a PCI-E Switch. This allows the independent expansion of CPU's or GPU's, which eliminates the use of redundant parts when performing upgrades from conventional architecture. A single GPU Box in the SR-AI Rack supports up to 16 NVIDIA Tesla GPU cards, providing better expansion capacity than current mainstream GPU servers with 4 cards or 8 cards. The SR-AI Rack can also cascade up to 4 GPU Boxes via the PCI-E Switch for up to 64 GPUs in one daisy chain, for a gigantic compressing computing resource pool. The NX5460M4 is a high-performance blade server of Inspur I9000; a converged architecture of the blade server series specially optimized for Deep Learning applications, which supports a maximum of 8 Deep Learning computing nodes and 16 GPU accelerator cards in a 12U space, as well as high-density servers, 4- and 8- socket key business servers, software defined storage and multiple computing schemes. This includes heterogeneous computing aimed at providing commercial corporate customers with the Deep Learning infrastructure, featuring high reliability, and high performance. Based on the next generation Intel® Xeon® processor microarchitecture, Inspur's new NF5280M5 enterprise rackmount server is ideal for enterprise cloud application, distributed file system server, ERP and small and medium-scale database, virtualization and high end enterprise applications. The AIStation is a complete AI deep learning cluster management system enabling simple and flexible deep learning, and makes it easy to train and combine popular model types across multiple GPUs and servers. It's also designed with speed, ease of control and efficient resource management in mind, allowing for a more flexible way to organize computation and puts the power of deep learning into the hands of engineers and data scientists. It's mainly used to analyze how AI applications occupy hardware and system resources when working on GPU clusters, reflecting the operational characteristics, hotspots and bottlenecks of the application, thus helping users make targeted adjustments and optimizations in the application algorithm. Caffe-MPI is an open source, clustered version of Caffe developed by Inspur, which enables Caffe, the industry's leading deep learning framework, to achieve efficient multi-node parallel learning. Caffe-MPI not only achieves better computational efficiency in standalone multi-GPU solutions, but also supports distributed cluster expansion. During GTC 2017, Hu Leijun, Vice President of Inspur, will host a technical session to talk about "The Path to End to End AI Solution", and give live presentations on several AI-related topics, such as "SR-AI Rack: Hyper-scale GPU Expansion Box by Inspur & Baidu" and "A High Performance Caffe on the Multi-Node Cluster" at Inspur boo Visit us at the NVIDIA GPU Technology Conference 2017, May 8~11, McEnery Convention Center in San Jose, California. For more information on Inspur's innovative GPU-accelerated solutions, visit www.inspursystems.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inspur-will-unveil-its-new-ai-supercomputer-and-aistation-at-gtc-2017-300452957.html


News Article | May 10, 2017
Site: www.eurekalert.org

Remote motion-sensitive photography, or camera trapping, is revolutionizing surveys of wild animal populations. Camera trapping is an efficient means of detecting rare species, conducting species inventories and biodiversity assessments, estimating site occupancy, and observing behaviour. If individual animals can be identified from the images obtained, camera trapping data can also be used to estimate animal density and population size - information critical to effective wildlife management and conservation. For this reason, camera traps were initially popularized by researchers studying big cats and other species with distinctive coat markings. Since then, thousands of camera traps have been deployed in wildlife habitat across the globe, especially in tropical forest ecosystems where animals are difficult to survey by other means. However, methods for estimating abundances of species which cannot be individually identified are still in development, and none is generally accepted or broadly applied. Researchers from the University of St Andrews, the Max Planck Institute for Evolutionary Anthropology (MPI-EVA) and the German Centre for Integrative Biodiversity Research (iDiv) recently extended distance sampling analytical methods to accommodate data from camera traps. "Distance sampling is a very well-established statistical framework for estimating animal density and population size that is already familiar to many ecologists", says Hjalmar Kühl of the MPI-EVA and iDiv. "This development will pave the way for researchers to estimate abundances of multiple species from camera trapping data collected over relatively short time intervals, without identifying individuals, and with minimal additional field work." Kühl adds: "This new approach can be easily integrated into our ongoing camera trap surveys across a broad range of habitats and species; we will also apply it in our monitoring work." The models are implemented in the free, Windows-based software Distance, and various packages of the statistics software R. Detailed documentation and advice from statisticians is also freely available via the Distance project website. Further testing and validation are recommended. Nevertheless, this development is an important addition to the set of analytical methods available to researchers conducting camera trap surveys. It can improve the quantity and quality of information about animal abundance and how it varies in space and time, facilitating effective conservation management. Stephen Buckland of the University of St. Andrews states: "Many animal populations are difficult to monitor effectively, but technological advances are opening up new strategies. The challenge for the statistician is to keep pace with the technological advances, and ensure that models are available to exploit fully the resulting data. This work is an important step in that direction." Eric Howe of the University of St. Andrews ads: "Given the current rates of species extinction and loss of biodiversity, I'm excited to be involved in research that has the potential to provide improved information to wildlife and conservation managers in a timely fashion." EH, SJ Howe EJ, Buckland ST, Després-Einspenner M-L, Kühl HS (2017): Distance sampling with camera traps. Methods in Ecology and Evolution, April 2017, DOI: 10.1111/2041-210X.12790


News Article | May 9, 2017
Site: www.prweb.com

Mohr Partners, Inc. (MPI), a commercial real estate advisory firm, has hired Eric A. Karl to serve as Chief Financial Officer (CFO), following the firms recent completion of a management buyout. He has more than 30 years of experience leading finance organizations, ten years with General Electric and 15 years as CFO or board member of private and public companies. Most recently he was CFO of 1A Smart Start, which grew 300% over six years to well over $100 million in revenue. Eric said, “I have been looking for the right opportunity to invest my time and expertise in an organization with great growth potential.” “Eric's successful track record of helping companies improve operational excellence in finance and operations ideally qualify him to support our aggressive growth plans.” stated Robert Shibuya, MPI Chairman & CEO. As a shareholder, Eric will also serve on MPI's board of directors and executive committee. About MPI: Mohr Partners, Inc. (MPI) is a global corporate real estate advisor, providing tenants and occupiers integrated solutions including portfolio management and lease administration, business intelligence consulting, research and site selection, location incentives practice, transaction advisors, and project management. Since 1986, MPI has been managing real estate portfolios for organizations across industries. MPI seamlessly provides global services through 18 offices across North America and its strategic alliance partners. For more information on MPI, please visit http://www.mohrpartners.com. This release may contain “forward-looking statements.” All statements, other than statements of historical fact, including statements that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management’s assumptions and assessments in light of experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results may differ significantly from those envisaged by our forward-looking statements. Among the factors that could cause actual results to differ materially from those described or implied in the forward-looking statements are general business and economic conditions, production delays resulting from lack of regulatory certifications and other factors, competition in our existing and future markets, lack of market acceptance of our products and services, the substantial leverage and debt service resulting from our indebtedness, loss or retirement of key executives and other risks disclosed by us or generally associated with our business.


News Article | May 8, 2017
Site: en.prnasia.com

SAN JOSE, Calif., May 9, 2017 /PRNewswire/ -- The GPU Technology Conference 2017 (GTC17) will be held from 9 to 11 May, in San Jose, USA. This year's GTC is set in 12 core themes, for example deep learning and artificial intelligence (AI), autonomous vehicles, virtual reality (VR) and augmented reality (AR), computer and machine vision, etc; setting up 654 small seminars, with 799 guests sharing their knowledge and experience on each of the GPU application field. During GTC 2017, Inspur and NVIDIA and will jointly present a cutting-edge AI supercomputer, AGX-2, with the NVLink™ 2.0 enabled. The AGX-2 is designed to provide maximum throughput for superior application performance for science and engineering computing - taking AI computing to the next level. Inspur, as a Platinum Sponsor, will also present various types of AI application-oriented servers, such as SR-AI Rack, NF5280M5, NX5460M4, and AIStation, a complete AI deep learning cluster management system. Below are the key highlights of the products displayed at Inspur booth (#911): The SR-AI Rack, jointly launched by Inspur and Baidu at Inspur Partner Forum (IPF) 2017 on April 26, is the world's first rack server that adopts a PCI-e Fabric interconnect architecture design. It breaks the traditional server GPU/CPU coupled architecture through connecting the upward CPU computing/scheduling node to the downward GPU Box using a PCI-E Switch. This allows the independent expansion of CPU's or GPU's, which eliminates the use of redundant parts when performing upgrades from conventional architecture. A single GPU Box in the SR-AI Rack supports up to 16 NVIDIA Tesla GPU cards, providing better expansion capacity than current mainstream GPU servers with 4 cards or 8 cards. The SR-AI Rack can also cascade up to 4 GPU Boxes via the PCI-E Switch for up to 64 GPUs in one daisy chain, for a gigantic compressing computing resource pool. The NX5460M4 is a high-performance blade server of Inspur I9000; a converged architecture of the blade server series specially optimized for Deep Learning applications, which supports a maximum of 8 Deep Learning computing nodes and 16 GPU accelerator cards in a 12U space, as well as high-density servers, 4- and 8- socket key business servers, software defined storage and multiple computing schemes. This includes heterogeneous computing aimed at providing commercial corporate customers with the Deep Learning infrastructure, featuring high reliability, and high performance. Based on the next generation Intel® Xeon® processor microarchitecture, Inspur's new NF5280M5 enterprise rackmount server is ideal for enterprise cloud application, distributed file system server, ERP and small and medium-scale database, virtualization and high end enterprise applications. The AIStation is a complete AI deep learning cluster management system enabling simple and flexible deep learning, and makes it easy to train and combine popular model types across multiple GPUs and servers. It's also designed with speed, ease of control and efficient resource management in mind, allowing for a more flexible way to organize computation and puts the power of deep learning into the hands of engineers and data scientists. It's mainly used to analyze how AI applications occupy hardware and system resources when working on GPU clusters, reflecting the operational characteristics, hotspots and bottlenecks of the application, thus helping users make targeted adjustments and optimizations in the application algorithm. Caffe-MPI is an open source, clustered version of Caffe developed by Inspur, which enables Caffe, the industry's leading deep learning framework, to achieve efficient multi-node parallel learning. Caffe-MPI not only achieves better computational efficiency in standalone multi-GPU solutions, but also supports distributed cluster expansion. During GTC 2017, Hu Leijun, Vice President of Inspur, will host a technical session to talk about "The Path to End to End AI Solution", and give live presentations on several AI-related topics, such as "SR-AI Rack: Hyper-scale GPU Expansion Box by Inspur & Baidu" and "A High Performance Caffe on the Multi-Node Cluster" at Inspur boo Visit us at the NVIDIA GPU Technology Conference 2017, May 8~11, McEnery Convention Center in San Jose, California. For more information on Inspur's innovative GPU-accelerated solutions, visit www.inspursystems.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inspur-will-unveil-its-new-ai-supercomputer-and-aistation-at-gtc-2017-300452957.html


News Article | May 10, 2017
Site: co.newswire.com

Leverage your customer and partner ecosystem for daily massive traffic and leads Are you tired of paying advertisements every day? Are you tired of paying monthly SEO services? The traditional lead generation is resource-intensive and very costly. The worst thing of the traditional approach is that there is no end to it. It is like sucking into a "black hole" with no way out. In this webinar, you will learn how to easily and quickly create your Virtual Collaborative Marketing model to: The 1st ten attendees will get a special bonus. Please register here: eZ-Xpo is a world leader in Virtual Collaborative Network empowering businesses to connect, collaborate, and promote through networks of virtual expo marketplaces for lead generation. eZ-Xpo reinvents the trade show and lead generation industry with a revolutionary new approach to virtual events, virtual trade shows, private business networking marketplace. eZ-Xpo delivers the world's 1st all-in-1 virtual expo marketplace that seamlessly integrates with built-in marketing automation to follow up with every prospective customer during and after the event. eZ-Xpo has been operating in San Francisco Silicon Valley for over five years. eZ-Xpo has deployed the world’s all-in-1 virtual expo marketplace, results-oriented virtual collaborative marketing solutions for different industries and industry leaders such as MPI, Wells Fargo, New York Life, MetaStock, Boeing, and Raytheon. For more information on eZ-Xpo, please visit www.eZ-Xpo.com


CAMBRIDGE, Massachusetts, et OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE : 4502) a annoncé aujourd'hui que les résultats de l’essai clinique pivot ALTA (ALK in Lung Cancer Trial of AP26113) de Phase 2 évaluant ALUNBRIG™ (brigatinib) chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC), localement avancé ou métastatique, positif à la kinase du lymphome anaplasique (ALK+) et résistant au crizotinib ont été publiés dans le Journal of Clinical Oncology (DOI: 10.1200/JCO.2016.71.5904 Journal of Clinical Oncology). L’étude révèle que, pour les patients ayant reçu une dose quotidienne unique de 180 mg de brigatinib après une période préparatoire de sept jours avec une dose quotidienne unique de 90 mg, le Comité d'examen indépendant (CEI) a déterminé un taux de réponse objective (TRO) confirmé de 53 %. Par ailleurs, 67 % des patients présentant des métastases au cerveau mesurables ayant reçu cette posologie ont obtenu une réponse objective intracrânienne confirmée. Takeda a récemment reçu une autorisation accélérée de l’Agence américaine des produits alimentaires et des médicaments (la « FDA ») pour ALUNBRIG dans le traitement des patients atteints d’un CPNPC métastatique ALK+ ayant vu leur maladie progresser ou qui sont intolérants au crizotinib. Cette indication est approuvée dans le cadre de l’autorisation accélérée sur la base du taux de réponse de la tumeur et de la durée de la réponse. L'approbation continue pour cette indication peut être subordonnée à la vérification et à la description du bénéfice clinique dans un essai confirmatoire. « Comme la moitié des patients atteints d’un CPNPC ALK+ traités avec le crizotinib verront leur maladie progresser dans un délai d’un an, dans de nombreux cas avec une propagation du cancer dans le cerveau, il est essentiel que nous disposions de nouveaux traitements efficaces, capables de faire face à ces mécanismes de résistance », a déclaré l'auteur-présentateur Dong-Wan Kim, docteur en médecine, docteur en philosophie et responsable du Cancer Clinical Trials Center au Seoul National University Hospital en Corée du Sud. « Les résultats de l’essai ALTA offrent aux cliniciens des informations importantes sur l’efficacité et l’innocuité du brigatinib chez les patients ayant vu leur maladie progresser en étant sous crizotinib, et montrent que le brigatinib est très efficace dans ce contexte, aussi bien systématiquement que dans le cerveau. » « La publication des résultats de l’essai ALTA de Phase 2 est un jalon important pour le programme clinique sur le brigatinib. Nous tenons à remercier les patients, leurs familles et soignants, ainsi que les investigateurs pour leur participation à cet essai et leur dévouement », a expliqué David Kerstein, docteur en médecine au département Recherche clinique en oncologie chez Takeda et l’un des auteurs de la publication. « Nous sommes impatients de partager des résultats additionnels sur ALUNBRIG provenant de nos études alors que nous continuons à développer le médicament pour répondre aux besoins médicaux non satisfaits des patients atteints d’un CPNPC ALK+. » ALTA, un essai multicentrique ouvert composé de deux groupes, a recruté 222 patients atteints d’un CPNPC ALK+, localement avancé ou métastatique, ayant vu leur maladie progresser en étant sous crizotinib, la norme de soin actuelle pour le traitement de première ligne dans le contexte métastatique. Les patients ont été randomisés selon un ratio 1:1 pour recevoir soit une dose quotidienne unique de 90 mg de brigatinib (90 mg ; groupe A), soit une dose quotidienne unique de 180 mg après une période préparatoire de sept jours à 90 mg en dose quotidienne unique (la posologie 180 mg ; groupe B). De plus, les patients ont été classés en fonction de la présence de métastases dans le cerveau au départ et de la meilleure réponse à un traitement antérieur avec le crizotinib. La mesure du paramètre primaire d'efficacité était un taux de réponse objective (TRO) confirmé selon les critères RECIST (Response Evaluation Criteria in Solid Tumours - Critères d’évaluation de la réponse pour les tumeurs solides) v1.1 par l’évaluation de l’investigateur. Les mesures des paramètres secondaires d'efficacités incluaient le TRO confirmé tel qu’évalué par un Comité d'examen indépendant (CEI), la durée de réponse (DR), la survie sans progression de la maladie (SSPM), le TRO intracrânien, la DR intracrânienne, la survie globale, l’innocuité et la tolérabilité. ALUNBRIG est un médicament anticancéreux ciblé découvert par ARIAD Pharmaceuticals, Inc., société rachetée par Takeda en février 2017. ALUNBRIG a reçu récemment une autorisation accélérée de l’Agence américaine des produits alimentaires et des médicaments (la « FDA ») pour le traitement des patients atteints de CPNPC ALK+ dont la maladie a progressé ou qui sont intolérants au crizotinib. Cette indication est approuvée dans le cadre de l’autorisation accélérée sur la base du taux de réponse de la tumeur et de la durée de la réponse. Le maintien de l'approbation pour cette indication peut être subordonné à une vérification et à la description du bénéfice clinique dans le cadre d’un essai confirmatoire. Le programme de développement clinique ALTA renforce davantage l’engagement continu de Takeda à mettre au point des thérapies innovantes pour les personnes atteintes d’un CPNPC ALK+ à travers le monde et les professionnels de la santé qui les traitent. En plus de l’essai ALTA de Phase 1/2 et de Phase 2 en cours, le brigatinib fait également l’objet d’études dans l’essai ALTA 1L de Phase 3 visant à évaluer son efficacité et son innocuité en comparaison du crizotinib chez les patients atteints d’un CPNPC ALK+, localement avancé ou métastatique, n’ayant pas reçu auparavant de traitement avec un inhibiteur de l’ALK. MISES EN GARDE ET PRÉCAUTIONS Maladie pulmonaire interstitielle (MPI)/Pneumonite : Des réactions indésirables graves, mettant en jeu le pronostic vital ou mortelles, de nature pulmonaire et évoquant la maladie pulmonaire interstitielle (MPI)/pneumonite, sont survenues avec ALUNBRIG. Dans l’essai ALTA (ALTA), une MPI/pneumonite est survenue chez 3,7 % des patients dans le groupe à 90 mg (dose quotidienne unique de 90 mg) et chez 9,1 % des patients dans le groupe 90→180 mg (dose quotidienne unique de 180 mg après une période préparatoire de sept jours à 90 mg en dose quotidienne unique). Des réactions indésirables évoquant une possible MPI/pneumonite sont survenues précocement (dans un délai de 9 jours après avoir commencé la prise d’ALUNBRIG ; délai d’apparition médian de 2 jours) chez 6,4 % des patients, des réactions de grade 3 ou 4 survenant chez 2,7 % d’entre eux. Surveiller l’apparition ou l’aggravation de symptômes respiratoires (par ex. dyspnée, toux, etc.), en particulier durant la première semaine de prise d’ALUNBRIG. Ne plus administrer ALUNBRIG aux patients présentant des symptômes respiratoires nouveaux ou s'aggravant, et évaluer rapidement pour détecter une MPI/pneumonite ou d'autres causes de symptômes respiratoires (per ex. embolie pulmonaire, progression tumorale ou pneumonie infectieuse). Pour une MPI/pneumonite de grade 1 ou 2, vous pouvez soit reprendre l'administration d'ALUNBRIG en réduisant la dose après récupération jusqu'au niveau de base, soit arrêter définitivement l'administration du médicament. Arrêter définitivement l'administration d'ALUNBRIG en cas de MPI/pneumonite de grade 3 ou 4, ou de retour d’une MPI/pneumonite de grade 1 ou 2. Bradycardie : Une bradycardie peut subvenir avec ALUNBRIG. Durant l'essai ALTA, des rythmes cardiaques inférieurs à 50 battements par minute (bpm) se sont produits chez 5,7 % des patients du groupe à 90 mg et chez 7,6 % des patients du groupe 90→180 mg. Une bradycardie de grade 2 s'est produite chez 1 (0,9 %) patient du groupe à 90 mg. Surveiller la fréquence cardiaque et la tension artérielle durant un traitement avec ALUNBRIG. Surveiller plus fréquemment les patients si l'utilisation concomitante d'un médicament connu pour causer de la bradycardie ne peut être évitée. En cas de bradycardie symptomatique, arrêter l'administration d'ALUNBRIG et évaluer les médications concomitantes qui sont connues pour causer de la bradycardie. Si un médicament concomitant connu pour causer de la bradycardie est identifié et son administration interrompue ou ajustée, reprendre l'administration d'ALUNBRIG au même dosage après la disparition de la bradycardie symptomatique ; sinon, réduire la dose d'ALUNBRIG après la disparition de la bradycardie symptomatique. Arrêter l'administration d'ALUNBRIG en cas de bradycardie potentiellement mortelle si aucun médicament contribuant concomitant n'est identifié. Troubles visuels : Durant l'essai ALTA, des réactions indésirables conduisant à des troubles visuels, notamment une vision floue, une diplopie et une acuité visuelle réduite, ont été signalées chez 7,3 % des patients traités avec ALUNBRIG dans le groupe à 90 mg et chez 10 % des patients dans le groupe 90→180 mg. Un œdème maculaire de grade 3 et une cataracte se sont produits chez un patient chacun du groupe 90→180 mg. Conseiller aux patients de signaler tout symptôme visuel. Arrêter l'administration d'ALUNBRIG et demander une évaluation ophtalmologique pour les patients présentant des symptômes visuels nouveaux ou s'aggravant, de grade 2 ou d'une gravité supérieure. Après récupération des troubles visuels de grade 2 ou 3 jusqu'au grade 1 ou au niveau de référence, reprendre l'administration d'ALUNBRIG en réduisant la dose. Arrêter définitivement le traitement avec ALUNBRIG en cas de troubles visuels de grade 4. Élévation de la créatine phosphokinase (CPK) : Durant l'essai ALTA, une élévation de la créatine phosphokinase (CPK) s'est produite chez 27 % des patients recevant ALUNBRIG dans le groupe à 90 mg et chez 48 % des patients dans le groupe 90→180 mg. L'incidence de l'élévation de la CPK de grade 3 ou 4 était de 2,8 % dans le groupe à 90 mg et de 12 % dans le groupe 90→180 mg. Une réduction de dose en raison d'une élévation de la CPK a été effectuée chez 1,8 % des patients dans le groupe à 90 mg et chez 4,5 % dans le groupe 90→180 mg. Conseiller aux patients de signaler toute douleur, sensibilité ou faiblesse musculaire inexpliquée. Surveiller les niveaux de CPK durant un traitement avec ALUNBRIG. Arrêter l'administration d'ALUNBRIG en cas d'élévation de la CPK de grade 3 ou 4. Après résolution ou récupération au grade 1 ou au niveau de référence, reprendre l'administration d'ALUNBRIG à la même dose ou à une dose réduite. Élévation des enzymes pancréatiques : Durant l'essai ALTA, une élévation de l'amylase s'est produite chez 27 % des patients du groupe à 90 mg et chez 39 % des patients du groupe 90→180 mg. Une élévation de la lipase s'est produite chez 21 % des patients du groupe à 90 mg et chez 45 % des patients du groupe 90→180 mg. Une élévation de l'amylase de grade 3 ou 4 s'est produite chez 3,7 % des patients du groupe à 90 mg et chez 2,7 % des patients du groupe 90→180 mg. Une élévation de la lipase de grade 3 ou 4 s'est produite chez 4,6 % des patients du groupe à 90 mg et chez 5,5 % des patients du groupe 90→180 mg. Surveiller la lipase et l'amylase durant un traitement avec ALUNBRIG. Arrêter l'administration d'ALUNBRIG en cas d'élévation des enzymes pancréatiques de grade 3 ou 4. Après résolution ou récupération au grade 1 ou au niveau de référence, reprendre l'administration d'ALUNBRIG à la même dose ou à une dose réduite. Toxicité embryo-fœtale : Sur la base de son mécanisme d'action et des résultats obtenus sur les animaux, ALUNBRIG peut nuire au fœtus en cas d'administration à des femmes enceintes. Il n'existe pas de données cliniques sur l'utilisation d'ALUNBRIG chez la femme enceinte. Informer les femmes enceintes du risque potentiel pour le fœtus. Conseiller aux femmes en âge de procréer d'utiliser un moyen de contraception non hormonal efficace durant un traitement avec ALUNBRIG, et pendant au moins 4 mois après l'administration de la dernière dose. Conseiller aux hommes ayant des partenaires féminines en âge de procréer d'utiliser un moyen de contraception efficace durant le traitement, et pendant au moins 3 mois après l'administration de la dernière dose d'ALUNBRIG. EFFETS INDÉSIRABLES Des réactions indésirables graves se sont produites chez 38 % des patients dans le groupe à 90 mg et chez 40 % des patients dans le groupe 90→180 mg. Les réactions indésirables graves les plus courantes ont été la pneumonie (5,5 % au total, 3,7 % dans le groupe à 90 mg et 7,3 % dans le groupe 90→180 mg) et la MPI/pneumonite (4,6 % au total, 1,8 % dans le groupe à 90 mg et 7,3 % dans le groupe 90→180 mg). Des réactions indésirables mortelles se sont produites chez 3,7 % des patients et ont pris la forme d'une pneumonie (2 patients), un décès soudain, une dyspnée, une insuffisance respiratoire, une embolie pulmonaire, une méningite bactérienne et une infection urinaire (1 patient pour chaque affection). Les réactions indésirables les plus communes (≥25 %) dans le groupe à 90 mg ont été la nausée (33 %), la fatigue (29 %), les céphalées (28 %) et la dyspnée (27 %) et, dans le groupe 90→180 mg, la nausée (40 %), la diarrhée (38 %), la fatigue (36 %), la toux (34 %) et les céphalées (27 %). Femmes et hommes en âge de procréer : Contraception : Conseiller aux femmes en âge de procréer d'utiliser un moyen de contraception non hormonal efficace durant un traitement avec ALUNBRIG, et pendant au moins 4 mois après l'administration de la dernière dose. Conseiller aux hommes ayant des partenaires féminines en âge de procréer d'utiliser un moyen de contraception efficace durant un traitement avec ALUNBRIG, et pendant au moins 3 mois après l'administration de la dernière dose. Utilisation gériatrique : Les études cliniques sur ALUNBRIG ne comprenaient pas un nombre suffisant de patients âgés de 65 ans ou plus pour déterminer s'ils répondent différemment des patients plus jeunes. Sur les 222 patients de l'essai ALTA, 19,4 % avaient entre 65 et 74 ans et 4,1 % avaient 75 ans ou plus. Aucune différence cliniquement pertinente quant à l'innocuité et à l'efficacité n'a été constatée entre les patients ≥65 ans et les patients plus jeunes. À propos de Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited est une société pharmaceutique mondiale axée sur la recherche et le développement, dont la mission est d'améliorer la santé et l'avenir des patients en traduisant la science en médicaments susceptibles de changer la vie. Takeda concentre ses efforts de R&D sur les domaines thérapeutiques de l’oncologie, de la gastroentérologie et du système nerveux central, ainsi que sur les vaccins. Takeda réalise sa R&D à la fois en interne et avec des partenaires en vue de se maintenir à l'avant-garde de l'innovation. Ses nouveaux produits innovants, notamment en oncologie et en gastroentérologie, ainsi que sa présence sur les marchés émergents, stimulent la croissance de Takeda. Plus de 30 000 employés de Takeda s’engagent à améliorer la qualité de vie des patients en collaborant avec nos partenaires du secteur des soins de santé dans plus de 70 pays. Pour de plus amples informations, visitez http://www.takeda.com/news.


News Article | May 15, 2017
Site: www.prweb.com

Mohr Partners, Inc. (MPI), a global corporate real estate advisory firm, today announced that Bridget Williams joined the company as Director of Portfolio Transaction Services and General Counsel in its Dallas headquarters office. Her focus will be oversight of the transaction management team. Before joining MPI, Ms. Williams served as Senior Counsel for Hartman, Simons and Wood, LLP. While there, Ms. Williams drafted and negotiated commercial real estate documents. In addition, Ms. Williams represented developers in the acquisition, development, and leasing of retail and mixed-use projects. “We are looking forward to Bridget joining us at MPI. Her legal, corporate, civic, and commercial real estate experience presents a rare skill set that is ideally suited to the evolution of our business as we advance our core service lines,” said Robert Shibuya, MPI Chairman, and CEO. Derith Jarvis, Managing Partner, Global Corporate Services said, “Bridget is a key hire with diverse experience that is the ideal complement to our expanding Global Corporate Services team.” Ms. Williams began her career in 1999, as an Associate for King Hershey, P.C. where she represented developers through each step of the real estate development process. She also worked for Sizewise, LLC as general counsel where she provided consultation to the corporate officers and executive team. Following, Ms. Williams served as the Assistant City Counselor for the City of Independence, Missouri. Ms. Williams also gained critical experience working for the Missouri Secretary of State’s Office as Director of Corporations Division and Counsel for Business Services Division. Later, Ms. Williams worked as a Real Estate Attorney and Leasing Manager for Hallmark, Inc. Ms. Williams drafted and negotiated retail leases for the company’s portfolio containing an estimated 2,000 corporate and licensee retail stores. Ms. Williams is a graduate of Northwestern University with a B.A. in Political Science and International Studies. Additionally, she is a graduate of the University of Missouri in Juris Doctor and Masters of Business Administration. ABOUT MPI: Mohr Partners, Inc. is a global corporate real estate firm, providing corporate tenants and occupiers with portfolio services including strategic planning, portfolio management and lease administration, research and site selection, incentive practice, project and construction management, and comprehensive demographics analysis. Since 1986, MPI has been managing real estate portfolios for organizations. The company has 19 offices in North America and seamlessly provides corporate real estate services globally through its strategic alliance partners. For more information on MPI, please visit http://www.mohrpartners.com. This release may contain “forward-looking statements.” All statements, other than statements of historical fact, including statements that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management’s assumptions and assessments in light of experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results may differ significantly from those envisaged by our forward-looking statements. Among the factors that could cause actual results to differ materially from those described or implied in the forward-looking statements are general business and economic conditions, production delays resulting from lack of regulatory certifications and other factors, competition in our existing and future markets, lack of market acceptance of our products and services, the substantial leverage and debt service resulting from our indebtedness, loss or retirement of key executives and other risks disclosed by us or generally associated with our business


Still images captured from video recorded by a camera trap set in Taï National Park, Côte D'Ivoire, 2014. In the top image a researcher records reference videos showing measured horizontal distances from the camera lens. The bottom image shows a Maxwell's duiker detected at the same location. Credit: MPI f. Evolutionary Anthropology Camera traps are a useful means for researchers to observe the behaviour of animal populations in the wild or to assess biodiversity levels of remote locations like the tropical rain forest. Researchers from the University of St Andrews, the Max Planck Institute for Evolutionary Anthropology and the German Centre for Integrative Biodiversity Research recently extended distance sampling analytical methods to accommodate data from camera traps. This new development allows abundances of multiple species to be estimated from camera trapping data collected over relatively short time intervals – information critical to effective wildlife management and conservation. Remote motion-sensitive photography, or camera trapping, is revolutionizing surveys of wild animal populations. Camera trapping is an efficient means of detecting rare species, conducting species inventories and biodiversity assessments, estimating site occupancy, and observing behaviour. If individual animals can be identified from the images obtained, camera trapping data can also be used to estimate animal density and population size – information critical to effective wildlife management and conservation. For this reason, camera traps were initially popularized by researchers studying big cats and other species with distinctive coat markings. Since then, thousands of camera traps have been deployed in wildlife habitat across the globe, especially in tropical forest ecosystems where animals are difficult to survey by other means. However, methods for estimating abundances of species which cannot be individually identified are still in development, and none is generally accepted or broadly applied. Researchers from the University of St Andrews, the Max Planck Institute for Evolutionary Anthropology (MPI-EVA) and the German Centre for Integrative Biodiversity Research (iDiv) recently extended distance sampling analytical methods to accommodate data from camera traps. "Distance sampling is a very well-established statistical framework for estimating animal density and population size that is already familiar to many ecologists", says Hjalmar Kühl of the MPI-EVA and iDiv. "This development will pave the way for researchers to estimate abundances of multiple species from camera trapping data collected over relatively short time intervals, without identifying individuals, and with minimal additional field work." Kühl adds: "This new approach can be easily integrated into our ongoing camera trap surveys across a broad range of habitats and species; we will also apply it in our monitoring work." The models are implemented in the free, Windows-based software Distance, and various packages of the statistics software R. Detailed documentation and advice from statisticians is also freely available via the Distance project website. Further testing and validation are recommended. Nevertheless, this development is an important addition to the set of analytical methods available to researchers conducting camera trap surveys. It can improve the quantity and quality of information about animal abundance and how it varies in space and time, facilitating effective conservation management. Stephen Buckland of the University of St. Andrews states: "Many animal populations are difficult to monitor effectively, but technological advances are opening up new strategies. The challenge for the statistician is to keep pace with the technological advances, and ensure that models are available to exploit fully the resulting data. This work is an important step in that direction." Eric Howe of the University of St. Andrews ads: "Given the current rates of species extinction and loss of biodiversity, I'm excited to be involved in research that has the potential to provide improved information to wildlife and conservation managers in a timely fashion." Explore further: New population of endangered cats found in Borneo More information: Eric J. Howe et al. Distance sampling with camera traps, Methods in Ecology and Evolution (2017). DOI: 10.1111/2041-210X.12790


Verato Demonstrates Value of Its Identity Matching Solutions for the Health Information Exchange Industry MCLEAN, VA--(Marketwired - May 11, 2017) - Verato, Inc., a leading provider of cloud-based patient matching and master patient index (MPI) solutions, today announced it has joined the Strategic Health Information Exchange Collaborative (SHIEC), the national trade association of health information exchanges (HIEs), as a Strategic Business and Technology (SB&T) Partner. Verato offers a next-generation approach to patient matching that can quickly be deployed as a master patient index (MPI) solution or as a cost-effective way to rapidly improve the matching performance of existing MPIs. SHIEC members like San Diego Health Connect, Healthix, and CRISP are using Verato to automatically resolve up to 75% of the potential duplicates their MPIs have flagged for manual resolution by a data steward. Additional HIEs around the country are in the beginning phases of deploying Verato as a cloud-based, lightweight MPI. "Historically, HIEs face some of the toughest possible patient-matching challenges," said Mark LaRow, CEO of Verato. "This is due to large, diverse, and geographically-concentrated patient populations; a range of different data governance standards across participating providers; and aggressive onboarding of new hospital systems and facilities. Verato has developed a totally new way to approach patient matching, and we're seeing HIEs across the country leverage our technology to dramatically improve their matching capabilities while saving time, effort and cost." "SHIEC is excited to have Verato join as a new SB&T Partner," said Pam Matthews, Interim Executive Director of SHIEC. "SB&T Partners are selected based on their ability to bring unique, value-added solutions to our HIE community members. Patient matching is an industry challenge faced by all HIEs, and Verato's technology services support HIEs in successfully meeting this challenge. SHIEC looks forward to our collaborative relationship with Verato." About Verato Verato offers a cloud-based matching platform that links and matches identities across disparate databases or organizations with the highest accuracy rates in the industry. Verato leverages an extensive self-learning database of US identities as a reference, or universal "answer key." Verato links identity information 15 times better than existing technologies. And because it is cloud-based, the Verato platform is less expensive, faster to implement, and more scalable than traditional matching technology. Verato is based in McLean, VA. For more information, visit www.verato.com. About SHIEC SHIEC is the national trade association of health information exchanges (HIEs) and strategic business and technology partners. Its 49-member HIE organizations manage and provide for the secure digital exchange of health data for hospitals, healthcare providers and other participants serving more than half of the U.S. patient population. As the unbiased data trustees in their communities, SHIEC member organizations are critical to advancing effective, efficient healthcare delivery locally, regionally and nationally to improve health. For more information about SHIEC or the executive director search: info@strategichie.com.


News Article | May 9, 2017
Site: www.eurekalert.org

Some scientists dream about big data. The dream bridges two divided realms. One realm holds lofty peaks of number-crunching scientific computation. Endless waves of big data analysis line the other realm. A deep chasm separates the two. Discoveries await those who cross these estranged lands. Unfortunately, data cannot move seamlessly between Hadoop (HDFS) and parallel file systems (PFS). Scientists who want to take advantage of the big data analytics available on Hadoop must copy data from parallel file systems. That can slow workflows to a crawl, especially those with terabytes of data. Computer Scientists working in Xian-He Sun's group are bridging the file system gap with a cross-platform Hadoop reader called PortHadoop, short for portable Hadoop. "PortHadoop, the system we developed, moves the data directly from the parallel file system to Hadoop's memory instead of copying from disk to disk," said Xian-He Sun, Distinguished Professor of Computer Science at the Illinois Institute of Technology. Sun's PortHadoop research was funded by the National Science Foundation and the NASA Advanced Information Systems Technology Program (AIST). The concept of 'virtual blocks' helps bridge the two systems by mapping data from parallel file systems directly into Hadoop memory, creating a virtual HDFS environment. These 'virtual blocks' reside in the centralized namespace in HDFS NameNode. The HDFS MapReduce application cannot see the 'virtual blocks'; a map task triggers the MPI file read procedure and fetches the data from the remote PFS before its Mapper function processes its data. In other words, a dexterous slight-of-hand from PortHadoop tricks the HDFS to skip the costly I/O operations and data replications it usually expects. Sun said he sees PortHadoop as the consequence of the strong desire for scientists to merge high performance computing with cloud computing, which companies such as Facebook and Amazon use to 'divide and conquer' data-intensive MapReduce tasks among its sea of servers. "Traditional scientific computing is merging with big data analytics," Sun said. "It creates a bigger class of scientific computing that is badly needed to solve today's problems." PortHadoop was extended to PortHadoop-R to seamlessly link cross-platform data transfer with data analysis and virtualization. Sun and colleagues developed PortHadoop-R specifically with the needs of NASA's high-resolution cloud and regional scale modeling applications in mind. High performance computing has served NASA well for their simulations, which crunch data through various climate models. Sun said the data generated from models combined with observational data are unmanageably huge and have to be analyzed and also visualized to more fully understand chaotic phenomena like hurricanes and hail storms in a timely fashion. PortHadoop faced a major problem in preparation to work with NASA applications. NASA's production environment doesn't allow any testing and development on its live data. PortHadoop developers overcame the problem with the Chameleon cloud testbed system, funded by the National Science Foundation (NSF). Chameleon is a large-scale, reconfigurable environment for cloud computing research co-located at the Texas Advanced Computing Center of the University of Texas at Austin and also at the the Computation Institute of the University of Chicago. Chameleon allows researchers bare-metal access, i.e., allows them to fully reconfigure the environment on its nodes including support for operations such as customizing the operating system kernel and console access. What's more, the Chameleon system of ~15,000 cores with Infiniband interconnect and 5 petabytes of storage adeptly blends in a variety of heterogeneous architectures, such as low-power processors, graphical processing units, and field-programmable gate arrays. "Chameleon helped us in different ways," Sun said. "First, it made it possible for us to create two different environments," each on a separate computer cluster of the bare metal system to mimic the NASA environment. "We are really happy that we were able to use Chameleon. The system helped us a great deal in our development," Sun added. Sun and colleagues installed some nodes with the traditional MPI, and on the other cluster they installed MapReduce. "Then we ran programs on these two different clusters and did the data integration, cross-platform data access, data analysis and visualization, all on Chameleon," Sun added. "Chameleon provides all functionality and scale of this computing facility, as well as the option of creating different programming environments on hardware resources with both HPC and data-intensive characteristics for our integration research." Sun and colleagues put PortHadoop-R to the test by using it in the NASA Cloud library project for empowering data management, diagnostics, and visualization of Cloud-Resolving Models (CRMs) of climate modeling. The NASA Cloud library has big data from satellites and human observations, with more than 70,000 datasets downloaded since April 2010 by 155 distinct users. The data are used for real-time forecasts of hurricane and other natural disasters; and for long-term climate prediction. "The ultimate goal is to generate a core cloud library that is dynamic and interactive with the user," said Wei-Kuo Tao, a senior research meteorologist at the NASA Goddard Space Flight Center. He leads the Goddard Mesoscale Dynamic and Modeling Group and is the principal investigator of the NASA AIST program. Tao and colleagues combine large-scale CRM simulation data at real time for data analysis and visualization. "The idea of the dynamic visualization and analysis with the Hadoop reader is that you don't have to copy the data," Tao said. "You can produce the visualization at the same time." Xian-He Sun spoke of the work that bridged the two types of storage systems. "We tested our PortHadoop-R strategy on Chameleon, and later confirmed these tests on NASA machines in practice. The result is fantastic, and beyond our expectation. We expected a 2-fold speedup. The result is a 15x speedup. The reason is that PortHadoop-R not only reduced one round disk copy but also utilized the concurrency of parallel file systems and Hadoop systems in a level which for general users would be difficult to achieve. In other words, PortHadoop-R has integrated the MPI and Hadoop systems," Sun said. "Chameleon was really helpful to provide the flexible environment so we can install, or simulate different environments. We have an HPC environment. We have a cloud environment. And we have them together and test them together. Chameleon in this sense provides us the ability to scale our computing resource and the privilege to control, optimize, and install our custom designed software environment to develop our software systems," Sun said. Building on the success with PortHadoop-R on real applications at NASA, Sun added that "the next step is to make PortHadoop-R more user-friendly. And, we would like to expand PortHadoop-R to support different application interfaces, so different users can use it easily." "In the long run, we would like to extend the merge at the OS level and at the user level. So, there are still a lot of things we need to do to support the seamless integration of the high-performance computing and big data analytics," Sun said.

Loading MPI collaborators
Loading MPI collaborators